We hypothesized that CCND1 and CCNE1 activation could represent a mechanism for palbociclib resistance in HNSCC, considering recent clinical data showing high CCNE1 as worse clinical outcome for palbociclib-treated patients in breast cancer (33, 34). This evidence concerns the gene CCNE1 and head and neck squamous cell carcinoma.